A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To date no comparative trials have been done, to our knowledge, of fixed-dose artemisinin combination therapies (ACTs) for the treatment of Plasmodium falciparum malaria in pregnancy. Evidence on the safety and efficacy of ACTs in pregnancy is needed as these drugs are being used increasingly throughout the malaria-affected world. The objective of this study was to compare the efficacy, tolerability, and safety of artemether-lumefantrine, the most widely used fixed ACT, with 7 d artesunate monotherapy in the second and third trimesters of pregnancy. METHODS AND FINDINGS: An open-label randomised controlled trial comparing directly observed treatment with artemether-lumefantrine 3 d (AL) or artesunate monotherapy 7 d (AS7) was conducted in Karen women in the border area of northwestern Thailand who had uncomplicated P. falciparum malaria in the second and third trimesters of pregnancy. The primary endpoint was efficacy defined as the P. falciparum PCR-adjusted cure rates assessed at delivery or by day 42 if this occurred later than delivery, as estimated by Kaplan-Meier survival analysis. Infants were assessed at birth and followed until 1 y of life. Blood sampling was performed to characterise the pharmacokinetics of lumefantrine in pregnancy. Both regimens were very well tolerated. The cure rates (95% confidence interval) for the intention to treat (ITT) population were: AS7 89.2% (82.3%-96.1%) and AL 82.0% (74.8%-89.3%), p = 0.054 (ITT); and AS7 89.7% (82.6%-96.8%) and AL 81.2% (73.6%-88.8%), p = 0.031 (per-protocol population). One-third of the PCR-confirmed recrudescent cases occurred after 42 d of follow-up. Birth outcomes and infant (up to age 1 y) outcomes did not differ significantly between the two groups. The pharmacokinetic study indicated that low concentrations of artemether and lumefantrine were the main contributors to the poor efficacy of AL. CONCLUSION: The current standard six-dose artemether-lumefantrine regimen was well tolerated and safe in pregnant Karen women with uncomplicated falciparum malaria, but efficacy was inferior to 7 d artesunate monotherapy and was unsatisfactory for general deployment in this geographic area. Reduced efficacy probably results from low drug concentrations in later pregnancy. A longer or more frequent AL dose regimen may be needed to treat pregnant women effectively and should now be evaluated. Parasitological endpoints in clinical trials of any antimalarial drug treatment in pregnancy should be extended to delivery or day 42 if it comes later. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86353884.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of artesunate in early pregnancy has not led to any additional toxic effects [135, 136].”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in Thailand the cure rate at day 42 was only 82%,138 possibly due to the low day 7 lumefantrine concentrations.”
From Malaria in pregnancy. (2013) · cites this paper as [138]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“AL was safe and well tolerated.136–138”
From Malaria in pregnancy. (2013) · cites this paper as [138]
In the citing paper
“However, application of highly sensitive molecular techniques confirmed that the frequency of low level (submicroscopic) infections is higher than expected in all endemic regions [16,17].”
From Submicroscopic infection of placenta by Plasmodium produces Th1/Th2 cytokine imbalance, inflammation and hypoxia in women from north-west Colombia (2014) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical assessment of gestational age in the newborn infant
Dubowitz, L. M. S., Dubowitz, V., & Goldberg, C. (1970) · The Journal of Pediatrics · doi:10.1016/s0022-3476(70)80038-5 · Cited by 2,241
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price, R. N., Uhlemann, A.-C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., Patel, R., Laing, K., Looareesuwan, S., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16767-6 · Cited by 853 · cited 1×
“Resistance is associated with an increase in Pfmdr1 copy numbers [33–35].”
BackgroundSelf-citationClinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine
White, N. J., van Vugt, M., & Ezzet, F. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00002 · Cited by 351
Self-citationPrice, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317 · cited 1×
“Parasites with increased Pfmdr1 copy number are also slightly less sensitive to artemisinin derivatives, although the differences are much less than for lumefantrine [36].”
BackgroundSelf-citationMalaria during pregnancy in an area of unstable endemicity.
Nosten, F., ter Kuile, F., Maelankirri, L., Decludt, B., & White, N. J. (1991) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(91)90205-d · Cited by 294 · cited 1×
“The ANCs provided early detection and treatment of malaria and reduced both morbidity and mortality [3].”
BackgroundSelf-citationEyes on the present and looking into the future
Piva, J. P., & Garcia, P. C. R. (2001) · Jornal de Pediatria · doi:10.2223/jped.98 · Cited by 279
Price, R. N., Cassar, C., Brockman, A., Duraisingh, M., van Vugt, M., White, N. J., Nosten, F., & Krishna, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2943 · Cited by 279 · cited 1×
“Resistance is associated with an increase in Pfmdr1 copy numbers [33–35].”
BackgroundSelf-citationGuyatt, H., & Snow, R. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.36 · Cited by 252 · cited 2×
“The newborn anthropometric results and neurological scores (Table 5) were very similar in the two groups and are consistent with having multiple malaria infections in pregnancy [18,43,45,46].”
BackgroundResultVugt, M. V., Wilairatana, P., Gemperli, B., Gathmann, I., Phaipun, L., Brockman, A., Luxemburger, C., White, N. J., Nosten, F., & Looareesuwan, S. (1999) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1999.60.936 · Cited by 194
Self-citationBrockman, A., Price, R. N., van Vugt, M., Heppner, D. G., Walsh, D., Sookto, P., Wimonwattrawatee, T., Looareesuwan, S., White, N. J., & Nosten, F. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90080-4 · Cited by 185 · cited 1×
“), but the exploratory analysis shows a clear superiority of AS7 over AL in this particular subgroup. There was no difference in efficacy between AL and AS7 in the treatment of primary or new infections. This difference between primary and recrudescent infections presumably reflects reduced class susceptibility of the…”
Self-citation
Cited by
WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group (2015) · BMC Medicine · doi:10.1186/s12916-015-0456-7 · Cited by 464
Malaria in pregnancy in the Asia-Pacific region
Rijken, M. J., McGready, R., Boel, M. E., Poespoprodjo, R., Singh, N., Syafruddin, D., Rogerson, S., & Nosten, F. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70315-2 · Cited by 181
Self-citationTakem, E. N., & D'Alessandro, U. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.010 · Cited by 185
“pyrimethamine; PF=parasitological failure; CR=clearance/cure rate; PE=parasitological efficacy; PK=pharmacokinetics; PNG=Papua New Guinea; *supervised quinine for 7 days; a peripheral microscopy, placental microscopy and placental histology; ‡ part of data in McGready 2001 [118], Mc Gready 2002 [149]; b data from McGr…”
BackgroundKajubi, R., Ochieng, T., Kakuru, A., Jagannathan, P., Nakalembe, M., Ruel, T., Opira, B., Ochokoru, H., Ategeka, J., Nayebare, P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32224-4 · Cited by 135
Drug-Resistant Malaria: The Era of ACT
Lin, J. T., Juliano, J. J., & Wongsrichanalai, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0099-y · Cited by 121
“There is increasing evidence that AL is safe in the second and third trimesters of pregnancy, though a longer course of treatment may be needed because of lower achieved plasma concentrations of artemether, dihydroartemisinin (DHA), and lumefantrine [ 32 ].”
Background
Metadata
- Authors
- McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F.
- Affiliations
- Mahidol University (TH)
- Shoklo Malaria Research Unit (TH)
- Corresponding author
- McGready, Rose
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-23
- Volume
- 5
- Issue
- 12
- Pages
- e253
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2605900
- OpenAlex
- W2008309617
- Cited by
- 136
- References
- 45
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 13
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Greater South Information System
- Funders
- Wellcome Trust
- Mahidol University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- artemether-lumefantrine, falciparum malaria, malaria in pregnancy, uncomplicated malaria, artemisinin-based combination therapy, cure rate, relapse, pharmacokinetics, lumefantrine, Karen women, birth outcomes, infant outcomes, safety and tolerability, northwestern Thailand
- MeSH terms
- Artesunate, Artemether, Lumefantrine, Adult, Animals, Antimalarials, Drug Therapy, Combination, Ethanolamines, Female, Fluorenes, Humans, Infant, Infant, Newborn, Plasmodium falciparum, Pregnancy, Thailand, Pregnancy Complications, Parasitic, Malaria, Falciparum, Parasitic Sensitivity Tests, Artemisinins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy. https://app.cochat.ai/papers/10.1371/journal.pmed.0050253
- The paper
- McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F. (2008). A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0050253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.